Dermata Therapeutics (DRMA) Stock Forecast, Price Target & Predictions
DRMA Stock Forecast
Dermata Therapeutics stock forecast is as follows: an average price target of $6.00 (represents a 471.43% upside from DRMA’s last price of $1.05) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
DRMA Price Target
The average price target for Dermata Therapeutics (DRMA) is $6.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential 471.43% upside from DRMA's last price of $1.05.
DRMA Analyst Ratings
According to 1 Wall Street analysts, Dermata Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for DRMA stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Dermata Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 21, 2024 | Anthony Vendetti | Maxim Group | $6.00 | $2.06 | 190.56% | 471.43% |
The latest Dermata Therapeutics stock forecast, released on Aug 21, 2024 by Anthony Vendetti from Maxim Group, set a price target of $6.00, which represents a 190.56% increase from the stock price at the time of the forecast ($2.06), and a 471.43% increase from DRMA last price ($1.05).
Dermata Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $6.00 |
| Last Closing Price | $1.05 | $1.05 | $1.05 |
| Upside/Downside | -100.00% | -100.00% | 471.43% |
In the current month, the average price target of Dermata Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Dermata Therapeutics's last price of $1.05. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 21, 2024 | Maxim Group | Buy | Buy | Hold |
| Feb 07, 2022 | Maxim Group | Hold | Initialise |
Dermata Therapeutics's last stock rating was published by Maxim Group on Aug 21, 2024. The company gave DRMA a "Buy" rating, the same as its previous rate.
Dermata Therapeutics Financial Forecast
Dermata Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Dermata Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. DRMA's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Dermata Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict DRMA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Dermata Therapeutics's previous annual EBITDA (undefined) of $NaN.
Dermata Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-979.45K | $-497.50K | $-684.06K | $-1.80M | $-2.33M | $-4.10M | $-2.56M |
| High Forecast | $-979.45K | $-497.50K | $-684.06K | $-1.80M | $-2.33M | $-4.10M | $-2.56M |
| Low Forecast | $-979.45K | $-497.50K | $-684.06K | $-1.80M | $-2.33M | $-4.10M | $-2.56M |
| Surprise % | - | - | - | - | - | - | - |
Dermata Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. DRMA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Dermata Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Dermata Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to DRMA last annual SG&A of $NaN (undefined).
Dermata Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.63 | $-0.32 | $-0.44 | $-1.16 | $-1.50 | $-2.64 | $-3.79 |
| High Forecast | $-0.63 | $-0.32 | $-0.44 | $-1.16 | $-1.50 | $-2.64 | $-3.79 |
| Low Forecast | $-0.63 | $-0.32 | $-0.44 | $-1.16 | $-1.50 | $-2.64 | $-3.79 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Dermata Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to DRMA previous annual EPS of $NaN (undefined).